BIOGEN INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
BIOGEN INC. (BIIB) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of -$1.32 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-10-21.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2015-10-21
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-09-30 was -$1.32M.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-06-30 was $145.00K, a 96.40% decline year-over-year.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2015-03-31 was $766.00K, a 24.46% decline year-over-year.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2014-12-31 was $6.56M.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2014 was $3.54M, a 333.01% increase from fiscal 2013.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2013 was $818.00K, a 66.67% decline from fiscal 2012.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2012 was $2.45M, a 66.33% decline from fiscal 2011.
- BIOGEN INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2011 was $7.29M, a 957.76% increase from fiscal 2010.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$1.32M 10-Q · filed 2015-10-21 | -$1.18M derived: sum of 2 quarters · filed 2015-10-21 | -$699.00K 10-Q · filed 2015-10-21 | $6.15M derived: sum of 4 quarters · filed 2015-10-21 |
| 2015-06-30 | $145.00K 10-Q · filed 2015-07-24 | $621.00K 10-Q · filed 2015-07-24 | $7.47M derived: sum of 3 quarters · filed 2015-07-24 | $7.47M derived: sum of 4 quarters · filed 2015-10-21 |
| 2015-03-31 | $766.00K 10-Q · filed 2015-04-24 | $7.33M derived: sum of 2 quarters · filed 2015-04-24 | $7.32M derived: sum of 3 quarters · filed 2015-10-21 | $11.35M derived: sum of 4 quarters · filed 2015-10-21 |
| 2014-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $6.56M derived: sum of 2 quarters · filed 2015-10-21 | $10.59M derived: sum of 3 quarters · filed 2015-10-21 | $3.54M 10-K · filed 2015-02-04 |
| 2014-09-30 | -$6.00K 10-Q · filed 2015-10-21 | $4.02M derived: sum of 2 quarters · filed 2015-10-21 | -$3.02M 10-Q · filed 2015-10-21 | -$699.00K derived: sum of 4 quarters · filed 2015-10-21 |
| 2014-06-30 | $4.03M 10-Q · filed 2015-07-24 | $3.02M 10-Q · filed 2015-07-24 | -$693.00K derived: sum of 3 quarters · filed 2015-07-24 | $2.95M derived: sum of 4 quarters · filed 2015-07-24 |
| 2014-03-31 | $1.01M 10-Q · filed 2015-04-24 | -$4.72M derived: sum of 2 quarters · filed 2015-04-24 | -$1.08M derived: sum of 3 quarters · filed 2015-04-24 | $2.49M derived: sum of 4 quarters · filed 2015-04-24 |
| 2013-12-31 | -$5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | -$2.10M derived: sum of 2 quarters · filed 2015-02-04 | $1.47M derived: sum of 3 quarters · filed 2015-02-04 | $818.00K 10-K · filed 2015-02-04 |
| 2013-09-30 | $3.64M 10-Q · filed 2014-10-22 | $7.21M derived: sum of 2 quarters · filed 2014-10-22 | $6.55M 10-Q · filed 2014-10-22 | $8.36M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-06-30 | $3.57M 10-Q · filed 2014-07-23 | $2.92M 10-Q · filed 2014-07-23 | $4.72M derived: sum of 3 quarters · filed 2015-02-04 | $5.60M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-03-31 | $654.00K 10-Q · filed 2014-04-23 | $1.15M derived: sum of 2 quarters · filed 2015-02-04 | $2.03M derived: sum of 3 quarters · filed 2015-02-04 | $2.08M derived: sum of 4 quarters · filed 2015-02-04 |
| 2012-12-31 | $496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $1.38M derived: sum of 2 quarters · filed 2015-02-04 | $1.43M derived: sum of 3 quarters · filed 2015-02-04 | $2.45M 10-K · filed 2015-02-04 |
| 2012-09-30 | $883.00K 10-Q · filed 2013-10-28 | $930.00K derived: sum of 2 quarters · filed 2013-10-28 | $1.96M 10-Q · filed 2013-10-28 | $2.24M derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-06-30 | $47.00K 10-Q · filed 2013-07-25 | $1.07M 10-Q · filed 2013-07-25 | $1.36M derived: sum of 3 quarters · filed 2014-02-06 | $2.15M derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-03-31 | $1.12M 10-Q · filed 2013-04-25 | $1.31M derived: sum of 2 quarters · filed 2014-02-06 | $2.10M derived: sum of 3 quarters · filed 2014-02-06 | $2.72M derived: sum of 4 quarters · filed 2014-02-06 |
| 2011-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $981.00K derived: sum of 2 quarters · filed 2014-02-06 | $1.60M derived: sum of 3 quarters · filed 2014-02-06 | $7.29M 10-K · filed 2014-02-06 |
| 2011-09-30 | $794.00K 10-Q · filed 2012-10-25 | $1.42M derived: sum of 2 quarters · filed 2012-10-25 | $7.10M 10-Q · filed 2012-10-25 | |
| 2011-06-30 | $621.00K 10-Q · filed 2012-07-24 | $6.31M 10-Q · filed 2012-07-24 | ||
| 2010-12-31 | $689.00K 10-K · filed 2013-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |